Could This Obscure Biotech Stock Make Early Investors a Fortune?
Plenty of promising biotech stocks on the market right now have slipped under the radar thanks to the COVID-19 pandemic. Akero Therapeutics (NASDAQ: AKRO) is one such company. Founded back in 2017 and only recently going public in mid-2019, Akero managed to attract a fair bit of excitement surrounding its only drug candidate, AKR-001. Thanks to encouraging early-stage clinical results, investors are once again starting to pay more attention to this this company.
While investing in small-cap biotech stocks is risky, there's also plenty of upside surrounding Akero Therapeutics. Will early investors end up making a fortune off of Akero, or would they do better to stay away from this alluring but risky biotech stock?
Image source: Getty Images.
Source Fool.com
